Single-cell sequencing yielded transcriptomic profiles for more than 20,000 cells, revealing gene expression changes that occur in response to treatment.
With revenues of $143,000, the company incurred a net loss of $9.1 million, or $0.14 per share, for the quarter, exceeding the consensus Wall Street estimate.
GenPro will use its EpiMarker machine-learning platform to identify a network of genomic DNA methylation sites in patients' circulating immune cells that may be predictive of drug response.
The agreement is Oncocyte's second distribution deal this year following an agreement with Core Diagnostics to sell the test in Africa and the Middle East.
The collaborators aim to develop lung cancer molecular diagnostic tests using molecular, clinical, and imaging-based artificial intelligence technologies.
Three research teams profiled proteomic, genomic, and other features in lung adenocarcinomas in Asia and other parts of the world, including cases in never-smokers.
The company recently presented results from its Aurora assay for multi-cancer screening and plans to launch a $100 test for the US and Chinese markets.
OncoCyte will cease further development of a liquid biopsy test that used an immune system interrogation approach to clarify whether patients’ lung nodules are benign.
